Explore the Agenda
EEG Focus Day
Tuesday, September 15
Pre-Conference Workshop Day
Tuesday, September 15
Day One
Wednesday, September 16
Day Two
Thursday, September 17
9:00 am Chair’s Opening Remarks & Welcome
Honing Standardization, AI Utility, Dose & Patient Selection to Sharpen EEG Strategy for More Effective Mood Therapeutics
9:20 am Precision Psychiatry 2.0: Reimagining Frameworks, Tools & Clinical Pathways to Deliver Individualized Mental Health Care
- Positioning EEG as a scalable, translational biomarker, integrating neural signals with clinical and biological data to improve patient stratification and development decision-making
- Moving beyond symptom-based diagnoses by leveraging EEG-derived neurophysiological signatures to reduce heterogeneity and define biologically coherent subgroups
- Translating EEG, digital phenotyping, and AI-enabled analytics from research tools into deployable assets across clinical trials, endpoints, and real-world settings
- Aligning pharmacological and non-pharmacological interventions with EEG-informed neural biomarkers to guide target engagement, dose selection, and personalized treatment strategies
9:50 am EEG & AI to Identify Glutamatergic Responders: A Path to Overcoming Schizophrenia’s Etiologic Heterogeneity
- Highlight the limitations of DSM 5 diagnostic categories in schizophrenia and illustrate how etiologic heterogeneity has contributed to repeated failures of mechanistically novel drug candidates
- Demonstrate how EEG derived cortical activity patterns, paired with AI driven analysis, can provide a mechanistic basis for prospectively identifying patients whose glutamatergic pathology aligns with specific therapeutic mechanisms
- Present evidence from pomaglumetad Phase 3 re analysis showing that baseline EEG markers can identify a ~20% subgroup with substantial cognitive and negative symptom improvement, revealing responders concealed within a non significant overall trial
- Outline how ongoing work in schizophrenia and autism aims to validate EEG based responder identification across disorders with shared cortical circuit disruption, supporting a broader precision therapy framework
10:20 am Morning Break
10:50 am Decoding EEG Biomarkers with Biophysical Models: A New Evidence Layer for Neuropsychiatric Drug Development
- Explaining how biophysically grounded neural models link EEG signals to underlying cell- and circuit-level mechanisms in health and neuropsychiatric disease
- Demonstrating how commonly used EEG biomarkers can be mechanistically interpreted to assess whether neurotherapeutics are acting on intended brain circuits
- Showing how EEG-based circuit modeling can build earlier, translational evidence of target engagement and dosing before human clinical trials
- Outlining the path from academic tool to pharma-facing platform, including spin-out efforts to support R&D decision-making and future treatment response prediction
11:20 am Roundtable Discussion: Toward True Standardization in EEG: Harmonizing Acquisition, Analysis & Data Infrastructure for Scalable, Regulatory-Ready Use
- Highlighting ongoing standardization efforts, such as IPEG’s recommendations, and how they provide a valuable foundation for common EEG acquisition and analysis practices
- Exploring opportunities to increase alignment across industry, academia, and technology partners to reduce variability and support more consistent analytical pipelines
- Discussing how emerging federated data infrastructures and shared EEG datasets can help establish reproducible, scalable analytical approaches across diverse clinical environments
- Identifying how unified standards and modern data frameworks can accelerate regulatory confidence, enhance trial comparability, and support broader adoption of EEG-based biomarkers
12:00 pm Lunch
Unlocking the Power of EEG & Sleep Biomarkers to Transform Diagnosis, Treatment Response & Precision Stratification
1:00 pm Decision Grade EEG Biomarkers to De Risk Early Neuropsychiatric Drug Development: Case Study in Fragile X & Schizophrenia
- Using EEG as a sensitive, translational readout of drug-target engagement in small first in human studies across Fragile X, schizophrenia, and other brain disorders
- Demonstrating rapid rescue and normalisation of disease relevant EEG signals following acute dosing and linking these changes to clinically meaningful cognitive outcomes
- Pairing EEG biomarkers with regulatory acceptable endpoints, including NIH Toolbox measures, to strengthen confidence in early proof of concept
- Applying EEG based responder identification to de risk progression into larger Phase 2 and 3 trials across heterogeneous neuropsychiatric populations
1:30 pm Roundtable Discussion: Establishing Normative EEG Signatures in Defined Psychiatric Subpopulations: Updates from ECMP & the Emerging Precision Landscape
- Differentiating insomnia subtypes (difficulty initiating vs. maintaining sleep vs. early awakening) and their relevance as biomarkers across depression and anxiety
- How insomnia signatures may stratify patients, predict symptom trajectories, or serve as endpoints across mood disorder trials
- Opportunities and pitfalls when using sleep related EEG and behavioral signals to map emotional blunting, anhedonia, and anxiety phenotypes
- Integrating clinical, sponsor, academic, and technology vendor perspectives to advance insomnia as a validated, scalable biomarker
2:00 pm Afternoon Networking Break
2:30 pm Translating Circuit Biology into Biomarkers: Integrating EEG, Electrophysiology, & Neural Signatures in Drug Development
- Leveraging EEG and complementary neurophysiology approaches to map circuit-level modulation and therapeutic mechanisms
- Combining immediate-early-gene readouts, single-unit recordings, and local field potentials to construct multi-modal circuit signatures
- Building translational frameworks that bridge preclinical circuit modulation to human biomarker endpoints
- Advancing biomarker-driven decision-making to de-risk development and guide dose selection, target engagement, and clinical translatability
3:15 pm Panel Discussion: Evaluating Unmet Needs in Sleep: Navigating EEG Utility & Limitations Across Complex Sleep Architecture
- Defining which facets of sleep (onset, maintenance, early awakening, quality, or EEG specific signals) truly matter as clinical biomarkers
- Understanding the practical and scientific limits of EEG in psychiatric sleep research: specificity, invasiveness, and placebo susceptibility
- How sponsors (orexin programs, sleep promoting or circadian targeting drugs) and EEG tech vendors interpret sleep architecture in different disease contexts
- Identifying core unmet needs in insomnia and sleep dysregulation across mood and psychiatric disorders, and what measurement innovation is required